Immunisation with a combination of two complementary feline calicivirus strains induces a broad cross-protection against heterologous challenges.
Feline calicivirus (FCV) is characterised by a high degree of antigenic variation potentially compromising vaccine efficacy. Inclusion of several FCV strains or antigens in current vaccines could be a means to improve protection against antigenically distinct isolates. This study evaluated the synergy between two FCV strains (FCVG1 and FCV431) by comparing immunity induced by either strain with that provided by a combination of the two strains against an heterologous challenge with antigenically distant FCV strains (FCV393 and FCV220). Thirty-two SPF kittens were randomly allocated to four groups of eight cats in each group. Groups B, C and D cats were vaccinated once subcutaneously with strains FCVG1, FCV431, and FCVG1 + FCV431, respectively. Each kitten received a total dose of 10(3.4) CCID50 of FCV. Control group A was not immunised. On day 31, four cats from each group were challenged oronasally with FCV220 and four cats with FCV393. Following challenge, the cats were monitored for clinical signs, viral shedding and antibody responses. FCV220 and FCV393 induced severe clinical signs in control cats typical of FCV infection. Immunisation with both strains mixed together induced higher neutralizing antibody titres against FCV220 and FCV393 strains on average. Protection was observed in all groups, however combination of the two strains resulted in a better clinical protection and reduction of virus shedding after heterologous challenge. A moderate correlation was observed between neutralizing antibody titres at the time of challenge and protection against clinical signs. These results indicated that vaccines combining antigens from different FCV strains may induce a broader heterologous protection.
Poulet
Hervé
H
Merial SAS, Lyon Laboratories, Research and Development Department, 254, rue Marcel Mérieux, 69007 Lyon, France. herve.poulet@merial.com
Brunet
Sylvie
S
Leroy
Vincent
V
Chappuis
Gilles
G
D000595:Amino Acid Sequence; D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D000940:Antigenic Variation / Q000235:genetics / Q000276:immunology; D001483:Base Sequence; D001831:Body Temperature; D017250:Caliciviridae Infections / Q000276:immunology / Q000662:veterinary* / Q000821:virology; D017927:Calicivirus, Feline / Q000235:genetics / Q000276:immunology*; D002371:Cat Diseases / Q000276:immunology / Q000517:prevention & control / Q000821:virology*; D002415:Cats; D019084:Fluorescent Antibody Technique, Indirect / Q000662:veterinary; D007114:Immunization / Q000662:veterinary*; D008969:Molecular Sequence Data; D009500:Neutralization Tests / Q000662:veterinary; D010802:Phylogeny; D012367:RNA, Viral / Q000737:chemistry / Q000235:genetics; D011897:Random Allocation; D020133:Reverse Transcriptase Polymerase Chain Reaction / Q000662:veterinary; D016415:Sequence Alignment; D017422:Sequence Analysis, DNA; D013047:Specific Pathogen-Free Organisms; D017201:Virus Shedding
D000914:Antibodies, Viral; D012367:RNA, Viral